Posting Date: March 18, 2021

Closing Date: March 28, 2027 11:30 a.m. ET

Reference Number: 21-025504

To: NCI Bid Board

From: Tanya Proctor
NCI CCR P-ARC
Tanya.proctor@nih.gov

Subject: NCI Bid Board Posting – Human AB Serum, 100ml – Heat Inactivated

The Surgery Branch of the National Cancer Institute is a combined laboratory and clinical research unit devoted to the development of innovative cancer immunotherapies and their translation to the treatment of patients with cancer. Efforts run the gamut from basic studies of cancer immunology to the conduct of clinical immunotherapy trials for patients with metastatic cancer. The Surgery Branch was responsible for the development of interleukin-2 (IL-2), the first effective immunotherapy in humans, the development of cell transfer immunotherapies for melanoma and other solid cancers, the first insertion of foreign genes into humans and the first development of effective human cancer immunotherapies based on the genetic engineering of autologous lymphocytes with genes encoding anti-tumor T cell receptors or chimeric antigen receptors.

The National Cancer Institute plans to purchase 200 Human AB Serum 100ml – heat inactivated from Valley Biomedical. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on March 28, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

As lots of Human Sera are highly variable we have a screening program to select the required material. This lot was selected as it most closely approximates the prior lot of serum that was purchased. Using other lots will impact the quality of the manufactured product, which in turn will impact the clinical trial, potentially affecting patient outcomes and the ability to interpret the outcome of a large clinical trial.

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request